GEMP Gemphire Therapeutics Inc.

9.54
-0.08  -1%
Previous Close 9.62
Open 9.73
Price To book 5.71
Market Cap 101439221
Shares 10,633,042
Volume 25,588
Short Ratio 6.16
Av. Daily Volume 98,109

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated in 2H 2017 with data due 2H 2018.
Gemcabene - AZURE-1
Nonalcoholic steatohepatitis (NASH) / Nonalcoholic fatty liver disease (NAFLD)
Phase 2b data due 1Q 2018.
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b data released August 7, 2017 - primary endpoint met but lower than expectations.
Gemcabene - ROYAL-1
Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2b data released June 28, 2017 - primary endpoint met.
Gemcabene - COBALT-1
Homozygous Familial Hypercholesterolemia (HoFH)